Search tips
Search criteria

Results 1-25 (68)

Clipboard (0)

Select a Filter Below

more »
Year of Publication
more »
1.  Multiple sclerosis: what can and cannot be done. 
British Medical Journal  1979;2(6204):1571-1572.
PMCID: PMC1597463  PMID: 534872
2.  Immunodiagnosis of cancer. 
British Medical Journal  1972;3(5827):641-642.
PMCID: PMC1785957  PMID: 5071703
3.  Letter: Effect of viruses on lymphocyte reactivity. 
British Medical Journal  1974;1(5901):245.
PMCID: PMC1633122  PMID: 4818173
7.  Letter: Linoleic acid in multiple sclerosis. 
British Medical Journal  1975;1(5955):456.
PMCID: PMC1672384  PMID: 1115975
12.  Polyunsaturated fatty acids in multiple sclerosis. 
British Medical Journal  1979;1(6169):1016-1017.
PMCID: PMC1598692  PMID: 435921
15.  Unsaturated fatty acids in multiple sclerosis. 
British Medical Journal  1973;2(5869):777-778.
PMCID: PMC1589818  PMID: 4718333
17.  Postviral syndrome 
PMCID: PMC1292896  PMID: 20894785
19.  Multiple sclerosis: what can and cannot be done. 
British Medical Journal  1980;280(6225):1230.
PMCID: PMC1601520  PMID: 6248156
21.  Lymphocyte sensitization to basic protein of brain in multiple sclerosis and other neurological diseases 
The number of lymphocytes in the blood sensitized to encephalitogenic factor (EF) is less in multiple sclerosis than it is in general paralysis of the insane. The number appears related to the extent of parenchymatous destruction. The study offers no support for the view that lymphocyte sensitization to EF is of pathogenetic significance in multiple sclerosis.
PMCID: PMC494749  PMID: 4135820
22.  Relation of measles virus to encephalitogenic factor with reference to the aetiopathogenesis of multiple sclerosis 
A combination of affinity chromatography with the macrophage electrophoretic migration (MEM) test has been used to study the antigenic similarities between encephalitogenic factor (EF) and measles virus. These have determinant(s) sufficiently closely related to account for the elevated level of circulating antibody to measles in multiple sclerosis.
PMCID: PMC494642  PMID: 4133588
23.  Specific Laboratory Test for Diagnosis of Multiple Sclerosis 
British Medical Journal  1974;1(5905):412-414.
Lymphocytes from patients with multiple sclerosis are much more susceptible to the inhibitory activity of linoleic acid (0·08 mg/ml) when tested for sensitization to thyroid by the macrophage electrophoretic mobility test (91% inhibition) than are those from normal subjects (57% inhibition). Cells from patients with a variety of other neurological diseases give 47% inhibition with linoleic acid. These differences are specific for multiple sclerosis and can be used as an in-vitro diagnostic test for the disease. Nearly 43% of clinically normal near relatives of patients with multiple sclerosis show an “anomalous” figure of about 77%; in the remainder the figure is the same as in the general population (57%). An anomalous result is compatible with lifelong freedom from M.S. Possibly a congenital anomalous handling of unsaturated fatty acids is a constant feature of the disease.
PMCID: PMC1633261  PMID: 4856264
24.  Lymphocyte sensitization to thymus and lymph node antigen in multiple sclerosis and other neurological diseases 
Circulating lymphocytes from patients with multiple sclerosis are sensitized to saline homogenate of human thymus. They also show a minor degree of sensitization to lymph node extract. The sensitization to thymus is greater in multiple sclerosis than it is in other neurological disease (except dementia paralytica) and this may be related to the degree of parenchymatous destruction which provides the antigen stimulus or to astroglial overgrowth in these diseases. The observations support the view that human brain and thymus may share antigen(s) of the type known as ø-antigen in mice.
PMCID: PMC494416  PMID: 4125963
25.  Rapid Development of a Cancer-like Antigen in Normal Tissue in vitro 
British Journal of Cancer  1973;27(6):427-433.
Freshly excised human embryonic tissue used as antigen to test lymphocytes from a cancer bearing patient gives a “normal tissue” result of about 10% in the macrophage electrophoresis migration (MEM) test. When, however, it is grown in vitro and then used as an antigenic stimulant to cancer lymphocytes, a “cancerlike” result (about 15%) is produced. These new antigenic determinant(s) akin to those associated with cancer basic protein appear rapidly (within 5.5 hours) in vitro. Cultures of “normal” cells are thus antigenically different from the same cells in context in vivo.
PMCID: PMC2008819  PMID: 4737227

Results 1-25 (68)